The Cell and Gene Therapy Industry Accelerates with New Financing, Partnerships, and Clinical Milestones
The cell and gene therapy (CGT) sector is entering the final quarter of 2025 with remarkable momentum, driven by major financing rounds, strategic partnerships, manufacturing advances, and promising clinical data. Collectively, these developments highlight a sector that continues to mature, moving from scientific promise to commercial and clinical reality.
Notable Announcements
Among the most notable announcements, Rarity PBC raised $4.6 million in seed financing to advance its gene therapy for ADA-SCID, also known as “bubble baby” disease. In parallel, the California Institute for Regenerative Medicine (CIRM) awarded $27 million to launch a new initiative aimed at expanding access to cell and gene therapies in underserved communities across California. This emphasis on equitable access underscores a broader shift toward inclusion and diversity in therapeutic development and delivery.
The financing front also saw substantial commitments from established players. Resilience announced long-term financing of up to $825 million to fuel its CDMO expansion strategy, reinforcing the critical role that manufacturing infrastructure plays in enabling the next generation of advanced therapies.
Additional transactions included Coya Therapeutics, which closed an upsized $23 million public offering, and Genprex, which secured up to $10 million in direct funding to support its oncology-focused gene therapy programs.
Strategic collaborations were another hallmark of the week. IASO Bio partnered with Korea’s GC Cell to bring CAR-T therapies to the Korean market, reflecting the globalization of cell therapy innovation. ICHORtec deepened its alliance with Johns Hopkins University to improve CRISPR gene-editing precision using its proprietary Quantum FMB® technology.
Meanwhile, NLS Pharmaceutics, Kadimastem, and TargetGene announced a joint initiative to advance next-generation, gene-edited cell therapies, while Chromatin Bioscience entered a new collaboration with Purespring Therapeutics.
Manufacturing Innovation
Manufacturing innovation also surged forward. Avantor® unveiled a next-generation sterile sampling platform and PUPSIT assemblies designed to meet the quality demands of cell and gene therapy production. Cellipont Bioservices partnered with Ernexa Therapeutics to manufacture ERNA-101 for ovarian cancer, while Ajinomoto Bio-Pharma Services joined forces with Olon S.p.A. to expand peptide and protein manufacturing capacity.
Similarly, Slingshot Biosciences integrated its TruCytes™ biomarker controls into Cellares’ automated Cell Q™ platform, enhancing quality and process control. Genenta Science and Anemocyte also partnered to develop off-the-shelf plasmid DNA for lentiviral vector production—a cornerstone of scalable gene therapy manufacturing.
Clinical Progress
On the clinical front, progress was equally compelling. REGENXBIO completed pivotal enrollment and initiated commercial production for its Duchenne muscular dystrophy gene therapy. BioCardia announced that the University of Wisconsin enrolled the first patient in its Phase 3 CardiAMP HF II cell therapy trial.
Sonoma Biotherapeutics and Kyverna Therapeutics both reported encouraging results from autoimmune disease trials, further validating the growing intersection between immunology and cell therapy.
Other highlights included positive data from Gamida Cell, VERIGRAFT, and Avobis Bio, along with advances from Johns Hopkins, CREATE Medicines, and Fate Therapeutics in targeted gene therapy and off-the-shelf CAR-T platforms.
Future Progress and Directions
Taken together, these updates reveal two defining trends shaping the field. First, capital and infrastructure investments are accelerating as companies race to scale manufacturing and shorten time-to-market. Second, accessibility is becoming a central theme, with new initiatives focused on underserved communities and global collaborations expanding therapeutic reach.
The cell and gene therapy ecosystem continues to evolve at a breathtaking pace, driven by science, sustained by capital, and united by a shared goal to bring novel, curative treatments to patients worldwide.